United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $5.56 by 10.97 percent. This is a 26.95 percent increase over earnings of $4.86 per share from the same period last year. The company reported quarterly sales of $677.700 million which beat the analyst consensus estimate of $623.966 million by 8.61 percent. This is a 33.70 percent increase over sales of $506.900 million the same period last year.
United Therapeutics Q1 2024 GAAP EPS $6.17 Beats $5.56 Estimate, Sales $677.700M Beat $623.966M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.